Your session is about to expire
← Back to Search
Topical Agent
GT20029 Gel for Acne Vulgaris
Phase 1
Waitlist Available
Research Sponsored by Suzhou Kintor Pharmaceutical Inc,
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up stage 1 is about 22 days and stage 2 is about 35 days
Summary
This trial tests a new medication called GT20029 on healthy people and those with hair loss or acne. Researchers want to see how the body processes the medication when applied to the skin and if it is safe.
Eligible Conditions
- Acne Vulgaris
- Acne
- Male Pattern Baldness
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ stage 1 is about 22 days and stage 2 is about 35 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~stage 1 is about 22 days and stage 2 is about 35 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse event
Skin irritation assessments
To characterize the PK AUC of GT20029
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: GT20029Experimental Treatment1 Intervention
Group II: GT20029 PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GT20029 Gel
2022
Completed Phase 1
~130
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Suzhou Kintor Pharmaceutical Inc,Lead Sponsor
16 Previous Clinical Trials
3,568 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger